Loading…
← CockpitCompetitor Analysis › MEDP Medpace Holdings, Inc.Open in the cockpit ↗

Medpace Holdings, Inc.MEDPCompetitor analysis, valuation and peers

United States · USD·Health Care›Miscellaneous Commercial Services

Contract research organization (CRO) providing outsourced clinical trial management services to small and mid-size biotech/pharma companies.

Momentum leader 90
Mkt cap
$18.1B
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$168M
20-day average traded
Fwd P/E
33.5×
forward earnings
ROIC−WACC
n/a
WACC 10.6%
Hurdle
+0 pp
Req g minus delivered
Next earnings
89 days
15 Feb 2027
Close · USD$646.87
1D-0.9%
1W-2.7%
1M+3.9%
3M+5.6%
6M+53.3%
YTD+15.2%
1Y+10.4%
ATR %3.0%
Beta0.68
52w lowhigh6.8% off high

What Medpace does

Contract research organization (CRO) providing outsourced clinical trial management services to small and mid-size biotech/pharma companies.

Is paid per trial, under contracts that run for years and bill in stages as work is completed, so booked-but-unfinished work (backlog) shows what revenue is coming. Its customers are mostly small and mid-sized biotechs, and it runs trials with its own staff rather than subcontracting parts. Founder August Troendle still leads it.

Products and services

  • Phase I-IV clinical trial management
  • Central laboratory services
  • Regulatory/medical affairs consulting

Customers

  • Small/mid-size biotech and pharma companies

Where it sits in the supply chain

  • Healthcare
  • Contract research organization (CRO)
  • Full-service clinical trial outsourcing

What could go right

  • Biotech clinical-trial outsourcing demand growth
  • Full-service model win rate vs larger CROs

What could go wrong

  • Biotech funding cycle sensitivity (smaller-biotech client base)
  • Clinical-trial cancellation/delay risk

Moat: narrow (process know-how, switching costs, scale). Deep therapeutic-area expertise and an integrated full-service model create switching costs once a trial is underway.

Headquarters: Cincinnati, Ohio, USA · Founded: 1992 · Employees: 6,200

Named competitors

Medpace at a glance

Size Medpace (MEDP) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $18.1B, the 517th largest of 3,085 United States companies the cockpit tracks. Shares closed at $646.87 on 18 Nov 2026.

Performance Over six months the shares gained 53.3%, against +30.4% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 15 in its peer set.

Growth Revenue grew 20.4% over the last twelve months (peer median +5.5%); the operating margin is 21.4% (peer median 3.6%).

Valuation It trades at 33.5× forward earnings against a peer median of 22.4× (2nd most expensive of 9).

Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Backlog Backlog (remaining performance obligations) was $3.80B at 30 Sep 2026, up 9% on a year earlier — 1.3 years of trailing revenue. Backlog detail →

Short interest Short interest is 5.0% of the free float (30 Oct 2026).

Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014016021 May 202621 Aug 202618 Nov 2026MEDP 150Peer median 132
Six months, rebased to 100: Medpace against the median of its 14 peers (local-currency closes).

Medpace financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.84B$2.53B$2.11B$1.89B$1.46B
Revenue growth—+20%+12%+29%—
Gross profit$800M$732M$627M$498M$410M
EBITDA$634M$563M$476M$363M$319M
Net income$518M$451M$404M$283M$245M
Free cash flow$668M$682M$572M$397M$351M
Capital expenditure$55.4M$31.4M$36.5M$36.6M$36.9M
Total debt$171M$137M$150M$164M$208M

Quarterly statements and history in the cockpit →

Medpace competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%CRLICLR22684523PGNYFTRESLNOABISBCANLEVTOCSEVHTECXMEDP6-month return →1-month return →
Up and to the right = strong over both horizons. Medpace is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%10×20×30×CRLICLR22684523PGNYFTRESBCEVHMEDPRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Medpace is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%CRLICLR22684523PGNYFTREOABISBCEVHMEDPGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Medpace is the large dot.

Medpace competitors and peer comparison

Head to head with its named competitors (MEDP vs ICLR vs IQV vs LH)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Medpace MEDP$18.1B+53%+20%21%33.5×22.3%
ICON ICLR$14.6B+70%+1%10%17.3×15.9%
Iqvia IQV$42.5B+50%+9%14%18.7×16.8%
Labcorp LH$30.1B+44%+6%11%19.3×14.5%

How Medpace compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Medpace against its 14 peers (data as of 18 Nov 2026)
MeasureMEDPPeer medianRank in peer set
1-month return+3.9%+0.6%6th highest of 15
6-month return+53.3%+30.4%6th highest of 15
Distance from 52-week high-6.8%-18.4%4th highest of 15
Revenue growth (TTM)+20.4%+5.5%3rd highest of 12
Operating margin21.4%3.6%3rd highest of 13
Forward P/E33.5×22.4×2nd most expensive of 9
Growth the price implies (Req g, 7 yrs)22.3%15.9%4th most demanding of 10
Growth delivered (Del g)+22.3%+6.7%4th highest of 10
Hurdle (Req g minus delivered)+0.0 pp-1.2 pp5th most demanding of 10
EV / EBITDA27.7×17.6×2nd most expensive of 7
Net debt / EBITDA-0.8×0.8×4th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Medpace MEDPUnited States$18.1B+53%+20%21%33.5×22.3%+22.3%
Charles River Laboratories CRLUnited States$16.0B+114%-1%15%26.2×25.6%+6.6%
ICON ICLRUnited States$14.6B+70%+1%10%17.3×15.9%+24.2%
WuXi XDC Cayman 2268.HKHong Kong$10.4B+20%+42%28%35.8×20.6%+126.4%
Eisai 4523.TJapan$9.36B+11%+11%6%26.6×10.7%+5.0%
Progyny PGNYUnited States$2.66B+41%+6%9%23.2×8.6%+30.2%
Fortrea FTREUnited States$1.98B+50%-3%2%21.6×31.9%+1.1%
Silence Therapeutics PLC Sponsored ADR SLNUnited States$1.23B+244%-98%-11,920%n/an/an/a
OmniAb OABIUnited States$741M+97%+91%-116%n/a60.6%-31.9%
SBC Medical SBCUnited States$645M+94%+7%40%11.7×-15.7%+6.7%
Adlai Nortye Ltd. Sponsored ADR ANLUnited States$610M-23%n/a-134%n/an/an/a
Evotec EVT.DEGermany$532M-46%-5%-15%n/an/an/a
Oculis OCSUnited States$456M-74%n/an/an/an/an/a
Evolent Health EVHUnited States$445M+2%+14%-1%9.2×14.0%+15.2%
Tectonic Therapeutic TECXUnited States$420M-27%n/an/an/an/an/a

Medpace backlog

Medpace reported $3.80B of remaining performance obligations at 30 Sep 2026, up 9% from a year earlier and up 9% from the previous quarter. That is 1.3 years of trailing revenue already under contract. Book-to-bill last quarter: 1.42.

Questions

Who are Medpace's main competitors?
Named competitors: ICON Plc (ICLR), IQVIA Holdings (IQV), Labcorp (Covance) (LH). The cockpit's measured peer set (industry) also includes Charles River Laboratories (CRL), ICON (ICLR), WuXi XDC Cayman (2268.HK), Eisai (4523.T), Progyny (PGNY), Fortrea (FTRE).
Is Medpace expensive compared with its peers?
On forward p/e it trades at 33.5× against a peer median of 22.4×, 2nd most expensive of 9 in its peer set. For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Medpace stock performed?
Over six months to 18 Nov 2026 the shares returned +53.3% against +30.4% for the median peer; over one year +10.4%.
What is Medpace's backlog?
Medpace's remaining performance obligations (contracted revenue not yet recognised) were $3.80B at 30 Sep 2026, +9% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.